Previous studies have shown this therapy upregulates neurotrophins, including VEGF and endothelial nitric oxide synthase (eNOS), in animal models of heart disease, vascular dementia, and Alzheimer’s disease ([8, 9]; S. H. [10]). Here, NOS3 is linked to early-onset autosomal dominant Alzheimer disease.